Bibliography
Found 27 results
Filters: Author is McArthur, Justin C [Clear All Filters]
Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. J Infect Dis. 2016 ;213(7):1065-73.
Apolipoprotein E ε4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals. J Neurovirol. 2016 ;22(5):607-614.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Cognitive Trajectory Phenotypes in Human Immunodeficiency Virus-Infected Patients. J Acquir Immune Defic Syndr. 2019 ;82(1):61-70.
. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010 ;67(5):552-8.
CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. J Neurovirol. 2015 ;21(5):559-67.
Efficacy and safety of two-drug regimens for treatment of HIV in the central nervous system. AIDS. 2020 ;34(13):1975-1977.
. Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol. 2012 ;18(2):81-90.
Genetic variation in iron metabolism is associated with neuropathic pain and pain severity in HIV-infected patients on antiretroviral therapy. PLoS One. 2014 ;9(8):e103123.
Is the glass three-quarters full or one-quarter empty?. J Infect Dis. 2006 ;194(12):1628-31.
. Health-related quality of life 'well-being' in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity. Psychosomatics. 2012 ;53(4):380-6.
Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology. 2012 ;433(2):498-505.
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011 ;17(1):3-16.
HIV-associated neurocognitive disorders: is there a hidden epidemic?. AIDS. 2010 ;24(9):1367-70.
. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008 ;64(5):566-72.
Impaired insulin sensitivity is associated with worsening cognition in HIV-infected patients. Neurology. 2019 ;92(12):e1344-e1353.
Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. 2016 ;22(2):170-8.
Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009 ;23(1):83-7.
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr. 2012 ;59(4):376-81.
Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS. 2012 ;26(7):890-3.
Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. Clin Infect Dis. 2015 ;61(9):1476-84.
Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol. 2012 ;18(6):511-20.
Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. J Neurovirol. 2016 ;22(4):479-87.
Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. J Infect Dis. 2017 ;215(1):105-113.